drugset / Trial / NCT04373512
Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury
Phase 2
Completed
182 enrolled
Medstar Health Research Institute
Children's National Research Institute · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
Timeline
- Start
- 2020-05-20
- Primary completion
- 2025-02-14
- Completion
- 2025-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lactobacillus GG | Other / unclassified | 2 unknown | — |
| Subject | Lactobacillus GG | Other / unclassified | 4 unknown | — |